Ischemic stroke as initial manifestation of systemic lupus erythematosus: A case report and review of the literature

Stefanos Ioannidisa,⁎, Michael Mavridisa, Panayiotis D. Mitsiasa,b

a Department of Neurology, University Hospital of Heraklion, University of Crete, Greece
b Department of Neurology & Comprehensive Stroke Center, Henry Ford Hospital, Detroit, MI, USA

ARTICLE INFO

Keywords:
- Ischemic stroke
- Systemic lupus erythematosus
- Initial manifestation
- Stroke in young patient

ABSTRACT

Stroke is a frequent occurrence among patients suffering from systemic lupus erythematosus (SLE), but it rarely occurs as the initial manifestation of the disease. We here present the case of a 37-year-old patient who developed an acute cerebellar ischemic stroke as initial event of SLE: elevated partial thromboplastin time and ESR, thrombocytopenia, anti-ds-DNA, anti-SSA, anti-JO-1, and the lupus anticoagulant were detected, and the diagnosis of SLE was established. In addition, we reviewed the literature in order to clarify the demographic, clinical, imaging and outcome characteristics of such a presentation, and found 10 similar cases. Most patients were young (age 31.7 ± 8.5 years) and women (8/11, 72.7%). Stroke most often affected the vertebrobasilar territory (7/11, 63.6%). The stroke mechanism was not clearly defined in these cases. Treatment with immunosuppression and anticoagulation was considered to be a reasonable choice for early secondary stroke prevention. The occurrence of ischemic stroke, primarily in the vertebrobasilar system among young patients, especially women, should always raise suspicion for underlying SLE, and prompt diagnostic investigations to confirm or exclude its presence.

1. Introduction

Systemic Lupus Erythematosus (SLE) is characterized by systemic inflammation, auto-antibodies and a relapsing-remitting course. SLE most often affects young women and is characterized by multi-system involvement. The central nervous system (CNS) is a frequent target of SLE, and its involvement leads to increased rates of morbidity and mortality [1].

Stroke events are frequent among patients suffering from SLE, affecting 3–20% of them, mainly in a young for stroke population, and usually within the first 5 years from diagnosis [1–4]. The diagnosis of SLE is usually established before any stroke occurrence [5]. The risk of stroke is 8 times higher in SLE patients compared to the general population [3], and the risk for cardiovascular events is increased by 3% every year after diagnosis [1]. All these are responsible for 20–30% of deaths among SLE patients [1].

There are several potential mechanisms for cerebrovascular disorders in SLE, including hypercoagulable states, cardiogenic embolism, premature or accelerated atherosclerosis, and rarely vasculitis [3]. The clinical expression is also variable as SLE can cause transient cerebral ischemia (TIA), arterial ischemic stroke, intraparenchymal hemorrhage, subarachnoid hemorrhage, and cerebral venous thrombosis [1].

While cerebrovascular vascular events are common among patients with SLE, ischemic stroke as the first manifestation of the disease is rare and it can often be misdiagnosed. We here present the case of a young patient who developed an acute cerebellar ischemic stroke as initial manifestation of SLE, and review the literature in order to identify the demographic, clinical, imaging and outcome characteristics of such a presentation.

2. Methods

We present the case of a young patient who developed an acute cerebellar ischemic stroke and was subsequently diagnosed with systemic lupus erythematosus. In addition, we performed a literature search in the database PubMed using the terms “stroke AND lupus AND first manifestation”, “stroke AND lupus AND initial manifestation”, “vascular AND lupus AND initial manifestation”, and “vascular AND lupus AND first manifestation”. We reviewed all papers published in the English language and also their references in order to discover additional cases.
3. Review of the literature

No neurological or functional abnormalities. The NIHSS score revealed no large vessel occlusion, aneurysm or dissection. Follow up at three and twelve months revealed left hemiataxia and gait ataxia, with otherwise unremarkable findings. Admission laboratory tests revealed elevated partial thromboplastin time (56.2 s), mild elevation of ESR (26 mm/1st hour), thrombocytopenia (100,000/μL, down from 415,000/μL 7 days earlier), strongly positive anti-ds-DNA (409WHO/mL), anti-SSA (102.5 U/mL), anti-JO-1 (94.6 U/mL), and presence of lupus anticoagulant. Testing for protein-C, protein-S, DNA (409WHO/mL), anti-SSA (102.5 U/mL), anti-JO-1 (94.6 U/mL), and C4 protein depression (409WHO/mL) was performed. CT or MRI scans results were reported in 9 patients and their findings were: positive anti-ds-DNA (n = 7), C3 and C4 protein depression (n = 6), elevated ESR (n = 5), positive antinuclear factor (n = 4), elevated DNA binding (n = 3), thrombocytopenia (n = 2), and lupus anticoagulant (n = 2). Treatment choices were reported in only 4 cases. In all, immunosuppressant therapy was used [IV prednisolone followed by oral prednisolone (n = 1), oral prednisolone (n = 2) and IV cyclophosphamide (n = 1)]. This was combined with IV anticoagulation followed by oral anticoagulation (n = 1), oral anticoagulation (n = 2) and dipyridamole (n = 1). Follow up data were scarcely documented. TIAs were reported in two cases (one with 2 episodes within 16–19 months, one with 5–6 episodes within 12 months). More permanent deficits were reported in two cases (in one case ataxia and dysarthria were reported at 6 months and in the other the patient was able to stand and walk with assistance at 9 months). Long-term cognitive impairment was reported in two cases. In our patient, no abnormal signs were found at the 3-month and 12-month follow-up, indicating fully recovery.

4. Discussion

Ischemic stroke as initial manifestation of SLE is an uncommon occurrence. It usually affects patients who are young, mostly women, and predominantly involves the vertebrobasilar territory. Treatment with immunosuppression and anticoagulation is a reasonable initial therapeutic approach.

It is not unusual to encounter ischemic stroke in the course of SLE [3,5,7]. This may be in part related to SLE disease activity and in part to the operation of classic stroke risk factors, such as hypertension, dyslipidemia and others, which often accompany SLE and its treatment [8,9]. However, it is very rare to encounter stroke as the initial event of the disease. The paucity of reported cases attests to this fact.

Stroke most often affects patients who are young, especially women. These demographic characteristics parallel those of the SLE population and are indirectly convincing that the stroke event was directly linked with SLE [10]. Also, our patient was young, had predisposition to autoimmune diseases and no other obvious factors for vascular events were found. These facts convinced us that the underlying etiology was the presence of active SLE.

It has been described that in SLE ischemic stroke is caused by several diverse mechanisms, including cardioembolism, large artery stenosis of either non-atherosclerotic or atherosclerotic etiology, arterial...
| Demographics relevant past history | Initial ischemic cerebrovascular event | Neuroimaging findings | Laboratory investigations | Treatment, follow-up & neurological outcome |
|-----------------------------------|---------------------------------------|-----------------------|--------------------------|-------------------------------------------|
| 29 y/o man \[5\]                | Transient quadriplegic, unable to move jaw or speech | Cerebral & left carotid angiography: normal | Positive antinuclear factor, Elevated DNA binding, Leukopenia, lymphopenia, C3 protein depression, Findings in renal biopsy | Treatment not reported, Two TIs after 16–19 months, Focal seizures after last episode |
| 32 y/o woman, pregnant \[5\]    | Transient left hemiparesis in immediate postpartum period | CT scan: normal | During pregnancy: Positive WR and VDRL, mild thrombocytopenia (30 x 10^9/l), positive antinuclear factor, Normal ESR, Three months postpartum: Severe thrombocytopenia (10 x 10^9/l), elevated DNA binding, positive anti-Sm antibody, C3 and C4 protein depression | Three months postpartum: Prednisone 60 mg per day, reducing to 10 mg per day, Five or six TIs within the next 12 months, Dipiridamole 400 mg per day was added, No further events for the next 8 months |
| 41 y/o woman, history of hepatitis and seronegative polyarthritis \[5\] | Recurrent episodes of right hemiparesis \[3\] during 3 years | CT scan: cerebral atrophy, right temporo-parietal infarct | Normal ESR, Ani-Sm antibody absent, IgG elevation, Findings in renal biopsy | Treatment not reported, Persistent right facial weakness, Progressive dementia followed |
| 46 y/o woman, history of paranoid psychosis \[5\] | Bilateral retinal artery occlusion | Serial isotope scan: right frontal lobe infarct | Elevated ESR, Three months later: positive antinuclear factor, elevated DNA binding, positive WR, C3 and C4 protein depression, renal function impairment | Treatment not reported, Focal and generalized seizures after 3 years, associated with prednisone-induced hyperglycaemia and severe hypotension, Aplasia, cognitive impairment, apraxic gait, bilateral extensor plantar response, Oral anticoagulation, IV cyclophosphamide monthly, 6-months follow-up ability to walk, ataxia, dysartria, No further events for the next 3 years |
| 16 y/o woman, history of skin red rash after sunlight exposure \[4\] | Multiple episodes of dizziness and headache | MRE: multiple vertebrobasilar territory infarcts | Leukocytosis, Positive ANA, Positive anti-ds-DNA, Positive direct Coombs Test | Positive anticoagulant, Follow-up not reported |
| 26 y/o woman \[4\]             | Acute headache, dizziness, dysarthria, ataxia | MRE: multiple vertebrobasilar territory infarcts | Anemia, Leukocytosis, Elevated ESR, Weakly positive anti-ds-DNA, Positive ANA, Positive direct Coombs Test, Lupus anticoagulant, LE cells absent | Antihypertensives, warfarin plus prednisolone, 9-months follow-up ability to stand and walk with assistance |
| 24 y/o woman \[12\]            | Acute headache, right hemiparesis and ataxia | CT scan: normal | Weakly positive ANA, Positive anti-ds-DNA, C3 and C4 protein depression, Normal ESR | Heparin IV, initially, Further treatment not reported, Follow-up not reported |
| 34 y/o man \[12\]             | Acute headache, dizziness, right hemi-and gait ataxia, dysphagia and right hypoperfusion | MRE: right cerebellar and pontine infarcts, CTA: right vertebral artery stenosis | Elevated ESR, Positive ANA, Positive anti-ds-DNA, Positive ASMA, C3 and C4 protein depression, LE cells absent, Normal ESR, Positive anti-ds-DNA, C3 and C4 protein depression | Treatment not reported, Follow-up not reported |
| 37 y/o woman \[12\]            | Acute dizziness, right hemiparesis, horizontal nystagmus, Previously misdiagnosed as Multiple Sclerosis | MRI: multiple cerebellar and pontine ischemic lesions | LE cells absent, Normal ESR, Positive anti-ds-DNA, C3 and C4 protein depression | Treatment not reported, Follow-up not reported |

(continued on next page)
Demographics, relevant past history | Initial ischemic cerebrovascular event | Neuroimaging findings | Laboratory investigations | Treatment, follow-up & neurological outcome
--- | --- | --- | --- | ---
27 y/o woman, 5th month of pregnancy | Catheter arteriogram: left internal carotid artery occlusion | Not applicable | Treatment unknown | No further events for the next 12 months

37 y/o man, history of rheumatoid arthritis with severe cardiovascular disease | Acute dizziness, left hemiataxia and gait ataxia | MRI: acute ischemic lesion in the territory of left SCA | Elevated APTT, elevated anti-SSA, positive lupus anticoagulant | High-dose IV corticosteroids, oral prednisolone, hydroxychloroquine, low-dose IV heparin, followed by acenocoumarol

Large vessel occlusion due to atherosclerosis is unusual in the early manifestations of systemic lupus erythematosus (SLE) and its manifestations. The occurrence of ischemic stroke, primarily the vertebrobasilar territory among young patients, especially women, is a potential early manifestation of systemic lupus erythematosus. No other findings, such as large vessel atherosclerosis, cerebral aneurysm, vasculitis, systemic premature atherosclerosis, dyslipidemia, hypertension, or diabetes mellitus were discovered.

The treatment choices were reported in only three of the cases we reviewed. In all of them, immunosuppressant therapy (either with oral prednisolone or IV cyclophosphamide) was used, in combination with oral anticoagulants or antiplatelet agent. For our patient we also elected to utilize immunosuppressant therapy (high dose IV corticosteroids, followed by oral prednisolone), hydroxycholecoleutine, and anticoagulation (IV heparin, followed by acenocoumarol). We feel that the combination of immunosuppressant and anticoagulation therapy is important for early secondary stroke prevention, because of the high activity of SLE and the high frequency of stroke recurrence after the initial vascular event.

Follow up data were scarcely documented in the literature cases were reviewed, and at present the occurrence of ischemic stroke as first manifestation of SLE cannot be correlated with specific outcomes, especially the risk of a second stroke, myocardial infarction or death. Our patient showed no abnormal signs at 3-months and 12-months, indicating fully recovery.

5. Conclusions
The diagnosis of SLE is always a challenge due to the wide variety of its manifestations. The occurrence of ischemic stroke, primarily in the vertebrobasilar territory among young patients, especially women, should always raise suspicion for underlying SLE, and prompt diagnostic investigations to confirm or exclude its presence.

References
[1] L.C. de Amorim, F.M. Maia, C.E. Rodrigues, Stroke in systemic lupus erythematosus and antiphospholipid syndrome: risk factors, clinical manifestations, neuroimaging, and treatment, Lupus 26 (5) (2017) 529–536.
[2] N. Futrell, C. Millikan, Frequency, etiology, and prevention of stroke in patients with systemic lupus erythematosus, Stroke 20 (5) (1989) 583–591.
[3] E. Krishnan, Stroke subtypes among young patients with systemic lupus erythematosus, Am. J. Med. 118 (12) (2005) 1415.e1-7.
[4] S.U. Kwon, J.Y. Koh, J.S. Kim, Vertebrobasilar artery territory infarction as an initial manifestation of systemic lupus erythematosus, Clin. Neurol. Neurosurg. 101 (1) (1999) 62–67.
[5] J.F. Haas, Stroke as an early manifestation of systemic lupus erythematosus, J. Neurol. Neurosurg. Psychiatry 45 (6) (1982) 554–556.
[6] M. Petri, A.M. Orbai, G.S. Alarcon, et al., Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus, Arthritis Rheum. 64 (8) (2012) 2677–2686.
[7] G.K. Berzins, J.P. Ioannidis, M. Aringer, et al., EULAR recommendations for the management of systemic lupus erythematosus with neurophysiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs, Ann. Rheum. Dis. 69 (12) (2010) 2074–2082.
[8] M. Fangtham, M. Petri, 2013 update: Hopkins lupus cohort, Curr. Rheumatol. Rep. 15 (9) (2013) 360.
[9] A.M. Bertoli, L.M. Vila, G.S. Alarcon, et al., Factors associated with arterial vascular

---

Table 1 (continued)

| Initial ischemic cerebrovascular event | Neuroimaging findings | Laboratory investigations | Treatment, follow-up & neurological outcome |
|---|---|---|---|
| 27 y/o woman, 5th month of pregnancy | Catheter arteriogram: left internal carotid artery occlusion | Not applicable | Treatment unknown |
| 37 y/o man, history of rheumatoid arthritis with severe cardiovascular disease | Acute dizziness, left hemiataxia and gait ataxia | MRI: acute ischemic lesion in the territory of left SCA | Elevated APTT, elevated anti-SSA, positive lupus anticoagulant |
| | | | High-dose IV corticosteroids, oral prednisolone, hydroxychloroquine, low-dose IV heparin, followed by acenocoumarol |
| Large vessel occlusion due to atherosclerosis is unusual in the early manifestations of systemic lupus erythematosus (SLE) and its manifestations. The occurrence of ischemic stroke, primarily the vertebrobasilar territory among young patients, especially women, should always raise suspicion for underlying SLE, and prompt diagnostic investigations to confirm or exclude its presence. | | | |

References
[1] L.C. de Amorim, F.M. Maia, C.E. Rodrigues, Stroke in systemic lupus erythematosus and antiphospholipid syndrome: risk factors, clinical manifestations, neuroimaging, and treatment, Lupus 26 (5) (2017) 529–536.
[2] N. Futrell, C. Millikan, Frequency, etiology, and prevention of stroke in patients with systemic lupus erythematosus, Stroke 20 (5) (1989) 583–591.
[3] E. Krishnan, Stroke subtypes among young patients with systemic lupus erythematosus, Am. J. Med. 118 (12) (2005) 1415.e1-7.
[4] S.U. Kwon, J.Y. Koh, J.S. Kim, Vertebrobasilar artery territory infarction as an initial manifestation of systemic lupus erythematosus, Clin. Neurol. Neurosurg. 101 (1) (1999) 62–67.
[5] J.F. Haas, Stroke as an early manifestation of systemic lupus erythematosus, J. Neurol. Neurosurg. Psychiatry 45 (6) (1982) 554–556.
[6] M. Petri, A.M. Orbai, G.S. Alarcon, et al., Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus, Arthritis Rheum. 64 (8) (2012) 2677–2686.
[7] G.K. Berzins, J.P. Ioannidis, M. Aringer, et al., EULAR recommendations for the management of systemic lupus erythematosus with neurophysiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs, Ann. Rheum. Dis. 69 (12) (2010) 2074–2082.
[8] M. Fangtham, M. Petri, 2013 update: Hopkins lupus cohort, Curr. Rheumatol. Rep. 15 (9) (2013) 360.
[9] A.M. Bertoli, L.M. Vila, G.S. Alarcon, et al., Factors associated with arterial vascular

---

Table 1 (continued)

| Initial ischemic cerebrovascular event | Neuroimaging findings | Laboratory investigations | Treatment, follow-up & neurological outcome |
|---|---|---|---|
| 27 y/o woman, 5th month of pregnancy | Catheter arteriogram: left internal carotid artery occlusion | Not applicable | Treatment unknown |
| 37 y/o man, history of rheumatoid arthritis with severe cardiovascular disease | Acute dizziness, left hemiataxia and gait ataxia | MRI: acute ischemic lesion in the territory of left SCA | Elevated APTT, elevated anti-SSA, positive lupus anticoagulant |
| | | | High-dose IV corticosteroids, oral prednisolone, hydroxychloroquine, low-dose IV heparin, followed by acenocoumarol |
| Large vessel occlusion due to atherosclerosis is unusual in the early manifestations of systemic lupus erythematosus (SLE) and its manifestations. The occurrence of ischemic stroke, primarily the vertebrobasilar territory among young patients, especially women, should always raise suspicion for underlying SLE, and prompt diagnostic investigations to confirm or exclude its presence. | | | |

References
[1] L.C. de Amorim, F.M. Maia, C.E. Rodrigues, Stroke in systemic lupus erythematosus and antiphospholipid syndrome: risk factors, clinical manifestations, neuroimaging, and treatment, Lupus 26 (5) (2017) 529–536.
[2] N. Futrell, C. Millikan, Frequency, etiology, and prevention of stroke in patients with systemic lupus erythematosus, Stroke 20 (5) (1989) 583–591.
[3] E. Krishnan, Stroke subtypes among young patients with systemic lupus erythematosus, Am. J. Med. 118 (12) (2005) 1415.e1-7.
[4] S.U. Kwon, J.Y. Koh, J.S. Kim, Vertebrobasilar artery territory infarction as an initial manifestation of systemic lupus erythematosus, Clin. Neurol. Neurosurg. 101 (1) (1999) 62–67.
[5] J.F. Haas, Stroke as an early manifestation of systemic lupus erythematosus, J. Neurol. Neurosurg. Psychiatry 45 (6) (1982) 554–556.
[6] M. Petri, A.M. Orbai, G.S. Alarcon, et al., Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus, Arthritis Rheum. 64 (8) (2012) 2677–2686.
[7] G.K. Berzins, J.P. Ioannidis, M. Aringer, et al., EULAR recommendations for the management of systemic lupus erythematosus with neurophysiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs, Ann. Rheum. Dis. 69 (12) (2010) 2074–2082.
[8] M. Fangtham, M. Petri, 2013 update: Hopkins lupus cohort, Curr. Rheumatol. Rep. 15 (9) (2013) 360.
[9] A.M. Bertoli, L.M. Vila, G.S. Alarcon, et al., Factors associated with arterial vascular
events in PROFILE: a Multiethnic Lupus Cohort, Lupus 18 (11) (2009) 958–965.

[10] J.H. Klippel, Systemic lupus erythematosus: demographics, prognosis, and outcome, J. Rheumatol. Suppl. 48 (1997) 67–71.

[11] P. Mitsias, S.R. Levine, Large cerebral vessel occlusive disease in systemic lupus erythematosus, Neurology 44 (3 Pt 1) (1994) 385–393.

[12] R. Mohammadian, A. Tarighatnia, M. Naghibi, et al., Vertebrobasilar artery stroke as the heralding sign of systemic lupus erythematosus, J. Stroke Cerebrovasc. Dis. 27 (5) (2018 May) e80–e85, https://doi.org/10.1016/j.jstrokecerebrovasdis.2017.12.003 https://www.ncbi.nlm.nih.gov/pubmed/?term=Vertebrobasilar+Artery+Stroke+as+the+Heralding+Sign+of+Systemic+Lupus+Erythematosus Epub 2018 Jan 3.

[13] A. Silverstein, Cerebrovascular accidents as the initial major manifestation of lupus erythematosus, New York State J. Med. 63 (1963) 2942–2948.